Press Release
In May 2025, Zhaoke reached a memorandum of agreement (“MOA”) with FAREVA, a French contract manufacturing organization who offers global expertise in household & industrial, beauty, makeup, pharmaceutical, and API products. According to the MOA, Zhaoke will become the recommended trusted partner for FAREVA’s customers who seek to manufacture pharmaceutical products in China..
Dr. Li Xiaoyi (Benjamin), Chairman of the Board, Executive Director and CEO of Zhaoke Ophthalmology, commented,
“At Zhaoke, our mission is to deliver high-quality ophthalmic treatments to patients worldwide. We are honoured that both our R&D and world-class manufacturing capabilities have been recognized by FAREVA, further validating our global standards. Developing drugs requires excellence at every stage – especially in R&D and manufacturing, where science becomes reality. Our state-of-the-art facility in Nansha, Guangzhou, China represents this commitment. Moreover, this strategic partnership also marks a significant step in our global expansion strategy. By joining forces with premier partners, we accelerate our ability to address unmet needs in eye care and expand access to cutting-edge therapies across key international markets.”
About FAREVA
Since its founding in 1990, French-based Fareva has become a trusted industrial partner across pharmaceuticals, cosmetics, household care and specialty chemicals. From bespoke R&D to full-scale production and packaging, Fareva delivers quality, flexibility and regulatory compliance every step of the way.
Today, the group employs 13,000 people, operates 41 production sites in 13 countries across 3 continents, and generated €2.22 billion in revenue in 2025.
In pharmaceuticals, Fareva supports clients “from molecule to market,” handling all dosage forms and scales—from pilot batches to commercial volumes. Backed by over 30 years of expertise and cutting-edge facilities, Fareva turns innovative ideas into tangible therapeutic solutions.
Zhaoke Ophthalmology has a comprehensive drug portfolio of innovative and generic treatments covering major eye diseases across both the front and the back of the eye. Currently, the company is focusing on major near-term development programs that are either in the NDA (New Drug Application) stage (i.e. CsA Ophthalmic Gel, NVK002 and TAB014), or in different stages in clinical trial (e.g. BRIMOCHOLTM PF, ZKY001) for the treatment of five respective major ophthalmic diseases, i.e. dry eye disease, myopia, wet AMD, presbyopia and cornea epithelial defects. Many drugs are being produced in its state-of-the-art, fully functional development and production facility in Nansha, Guangzhou, Guangdong Province.
Through its ambitious growth strategy, which includes partnering with domestic and international pharmaceutical companies, Zhaoke Ophthalmology aims to become a global leader in ophthalmology.
Media Contact :
FAREVA
Julie Ferraris – Group Communications Director
Tél. : +33 (0)6 58 38 61 39
Adresse e-mail : jferraris.corporate@fareva.com